Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has received the European Medicines Agency's (EMA) acceptance for reviewing its application for axitinib for the treatment of patients who are suffering from advanced renal cell carcinoma (RCC) after failure of prior systemic treatment.
Subscribe to our email newsletter
Axitinib is an oral and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2 and 3 that can influence tumor growth, vascular angiogenesis and progression of cancer (the spread of tumors).
Pfizer has filed the application on the basis of Phase 3 results from AXIS 1032 trial.
Pfizer Oncology Business Unit president and general manager Garry Nicholson said this regulatory filing for their investigational therapy axitinib, as well as ongoing studies of their existing medications, underscore Pfizer’s commitment to patients with advanced RCC.